AU2015301071C1 - Interleukin-2/Interleukin-2 Receptor alpha fusion proteins and methods of use - Google Patents

Interleukin-2/Interleukin-2 Receptor alpha fusion proteins and methods of use Download PDF

Info

Publication number
AU2015301071C1
AU2015301071C1 AU2015301071A AU2015301071A AU2015301071C1 AU 2015301071 C1 AU2015301071 C1 AU 2015301071C1 AU 2015301071 A AU2015301071 A AU 2015301071A AU 2015301071 A AU2015301071 A AU 2015301071A AU 2015301071 C1 AU2015301071 C1 AU 2015301071C1
Authority
AU
Australia
Prior art keywords
thr
leu
glu
ser
gln
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015301071A
Other languages
English (en)
Other versions
AU2015301071A1 (en
AU2015301071B2 (en
Inventor
Thomas Malek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53836871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015301071(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Miami filed Critical University of Miami
Publication of AU2015301071A1 publication Critical patent/AU2015301071A1/en
Application granted granted Critical
Publication of AU2015301071B2 publication Critical patent/AU2015301071B2/en
Priority to AU2020203352A priority Critical patent/AU2020203352B2/en
Publication of AU2015301071C1 publication Critical patent/AU2015301071C1/en
Priority to AU2022204034A priority patent/AU2022204034A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
AU2015301071A 2014-08-06 2015-08-05 Interleukin-2/Interleukin-2 Receptor alpha fusion proteins and methods of use Active AU2015301071C1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020203352A AU2020203352B2 (en) 2014-08-06 2020-05-22 Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
AU2022204034A AU2022204034A1 (en) 2014-08-06 2022-06-10 Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462033726P 2014-08-06 2014-08-06
US62/033,726 2014-08-06
PCT/US2015/043792 WO2016022671A1 (en) 2014-08-06 2015-08-05 Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020203352A Division AU2020203352B2 (en) 2014-08-06 2020-05-22 Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

Publications (3)

Publication Number Publication Date
AU2015301071A1 AU2015301071A1 (en) 2017-02-02
AU2015301071B2 AU2015301071B2 (en) 2020-03-05
AU2015301071C1 true AU2015301071C1 (en) 2020-07-02

Family

ID=53836871

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015301071A Active AU2015301071C1 (en) 2014-08-06 2015-08-05 Interleukin-2/Interleukin-2 Receptor alpha fusion proteins and methods of use
AU2020203352A Active AU2020203352B2 (en) 2014-08-06 2020-05-22 Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
AU2022204034A Abandoned AU2022204034A1 (en) 2014-08-06 2022-06-10 Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020203352A Active AU2020203352B2 (en) 2014-08-06 2020-05-22 Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
AU2022204034A Abandoned AU2022204034A1 (en) 2014-08-06 2022-06-10 Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

Country Status (32)

Country Link
US (3) US12084483B2 (enExample)
EP (2) EP3177307B1 (enExample)
JP (3) JP6723982B2 (enExample)
KR (1) KR102653758B1 (enExample)
CN (2) CN107074967B (enExample)
AU (3) AU2015301071C1 (enExample)
BR (1) BR112017001940A2 (enExample)
CA (1) CA2957273C (enExample)
CL (1) CL2017000284A1 (enExample)
CO (1) CO2017002166A2 (enExample)
DK (1) DK3177307T3 (enExample)
EA (2) EA202091342A3 (enExample)
ES (1) ES2986097T3 (enExample)
FI (1) FI3177307T3 (enExample)
HR (1) HRP20241258T1 (enExample)
HU (1) HUE068478T2 (enExample)
IL (2) IL250007B (enExample)
LT (1) LT3177307T (enExample)
MA (2) MA40094B1 (enExample)
MX (1) MX388977B (enExample)
MY (1) MY180831A (enExample)
PE (1) PE20170503A1 (enExample)
PH (1) PH12017500042A1 (enExample)
PT (1) PT3177307T (enExample)
RS (1) RS65930B1 (enExample)
SA (1) SA517380842B1 (enExample)
SG (2) SG11201700706WA (enExample)
SI (1) SI3177307T1 (enExample)
SM (1) SMT202400414T1 (enExample)
TN (1) TN2017000020A1 (enExample)
WO (1) WO2016022671A1 (enExample)
ZA (1) ZA201700245B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
LT3102595T (lt) 2014-02-06 2019-01-25 F. Hoffmann-La Roche Ag Interleukino-2 sulieti baltymai ir jų panaudojimas
MA40094B1 (fr) * 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
US12202856B2 (en) * 2016-05-19 2025-01-21 The General Hospital Corporation Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity
KR20190057113A (ko) 2016-09-28 2019-05-27 조마 (유에스) 엘엘씨 인터루킨-2에 결합하는 항체 및 그 용도
AU2018234810B2 (en) 2017-03-15 2023-05-11 Pandion Operations, Inc. Targeted immunotolerance
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2019113221A1 (en) 2017-12-06 2019-06-13 The Board Of Trustees Of The Leland Stanford Junior University Engineered proteins to enhance sensitivity of a cell to il-2
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2019183389A1 (en) * 2018-03-23 2019-09-26 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
BR112020018709A2 (pt) 2018-03-28 2021-01-05 Bristol-Myers Squibb Company Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso
EP3941935A1 (en) * 2019-03-18 2022-01-26 Biontech Cell & Gene Therapies Gmbh Interleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells
CN111944036B (zh) 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
US11739146B2 (en) 2019-05-20 2023-08-29 Pandion Operations, Inc. MAdCAM targeted immunotolerance
EP3976638A4 (en) * 2019-05-24 2023-08-23 Proviva Therapeutics (Hong Kong) Limited IL-2 COMPOSITIONS AND METHODS OF USE THEREOF
US11246906B2 (en) * 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy
AU2020315282A1 (en) * 2019-07-12 2022-02-10 Proviva Therapeutics (Hong Kong) Limited IL-2 compositions and methods of use thereof
AU2020316002A1 (en) * 2019-07-25 2022-03-03 The University Of Chicago Compositions and methods comprising protease-activated therapeutic agents
US20220378933A1 (en) * 2019-09-19 2022-12-01 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
KR20220084066A (ko) * 2019-10-18 2022-06-21 엘커메스 파마 아일랜드 리미티드 면역 체크포인트 억제제와 조합된 면역조절성 il-2 제제
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
WO2021222762A2 (en) 2020-04-30 2021-11-04 Aetio Biotherapy, Inc. Activatable il2 composition and methods of use
WO2022036079A1 (en) * 2020-08-13 2022-02-17 Bristol-Myers Squibb Company Methods of redirecting of il-2 to target cells of interest
TW202317623A (zh) * 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
AU2023219190A1 (en) * 2022-02-11 2024-08-15 Mural Oncology, Inc. Compositions and methods for cancer immunotherapy
EP4479090A4 (en) * 2022-02-16 2025-08-27 Univ Miami IL-2 AND TL1A FUSION PROTEINS AND METHODS OF USE THEREOF
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
CN120752258A (zh) * 2023-02-22 2025-10-03 百奥赛图(北京)医药科技股份有限公司 抗il2ra抗体及其用途
WO2025207491A1 (en) * 2024-03-25 2025-10-02 Mural Oncology, Inc. Compositions and methods for cancer immunotherapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014023752A1 (en) * 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
FR2619719B1 (fr) 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
US5250296A (en) * 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
ES2196098T3 (es) * 1994-12-28 2003-12-16 Univ Kentucky Res Found Secuencias anticuerpos anti-idiotipo 3h1 monoclonales relacionadas con el antigeno carcinoembrionico humano.
US6967092B1 (en) * 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
DE19701141C1 (de) * 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
JPWO2003029475A1 (ja) 2001-09-28 2005-01-20 株式会社ディナベック研究所 エピトープ結合β２ｍをコードする哺乳動物細胞感染性ウイルスベクターおよびその利用
RU2006135112A (ru) 2004-03-05 2008-04-10 Чирон Корпорейшн (Us) Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам
MX2007014474A (es) 2005-05-17 2008-02-07 Univ Connecticut Composiciones y metodos para inmunomodulacion en un organismo.
CN101255197B (zh) * 2008-03-28 2012-01-25 浙江海正药业股份有限公司 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
EP2553101A4 (en) 2010-04-02 2013-09-04 Univ Rochester PROTEASE-ACTIVATED CYTOKINES
WO2012088383A2 (en) 2010-12-23 2012-06-28 Genentech, Inc. PILR alpha INTERACTIONS AND METHODS OF MODIFYING SAME
SI3401402T1 (sl) * 2012-06-08 2021-03-31 Alkermes Pharma Ireland Limited Ligandi modificirani s krožno permutacijo kot agonisti in antagonisti
WO2014100913A1 (en) 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014023752A1 (en) * 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof

Also Published As

Publication number Publication date
KR102653758B1 (ko) 2024-04-04
TN2017000020A1 (en) 2018-07-04
NZ766851A (en) 2024-07-26
DK3177307T3 (da) 2024-10-07
EP3177307A1 (en) 2017-06-14
EP4438621A2 (en) 2024-10-02
AU2022204034A1 (en) 2022-07-14
WO2016022671A1 (en) 2016-02-11
PT3177307T (pt) 2024-09-13
MA40721B1 (fr) 2024-08-30
ZA201700245B (en) 2024-06-26
JP7272663B2 (ja) 2023-05-12
US20230079120A1 (en) 2023-03-16
JP2017523789A (ja) 2017-08-24
EA202091342A2 (ru) 2020-11-30
SG11201700706WA (en) 2017-02-27
AU2020203352B2 (en) 2022-03-10
CN107074967B (zh) 2021-06-08
LT3177307T (lt) 2024-08-12
CO2017002166A2 (es) 2017-05-19
HRP20241258T1 (hr) 2024-12-06
MA40094A1 (fr) 2021-09-30
AU2020203352A1 (en) 2020-07-02
US20170233448A1 (en) 2017-08-17
RS65930B1 (sr) 2024-10-31
SG10201913695PA (en) 2020-03-30
MY180831A (en) 2020-12-10
CN107074967A (zh) 2017-08-18
NZ728042A (en) 2024-07-26
AU2015301071A1 (en) 2017-02-02
IL275944B (en) 2022-02-01
PH12017500042A1 (en) 2017-05-22
EP4438621A3 (en) 2024-12-18
SMT202400414T1 (it) 2024-11-15
MX2017001062A (es) 2017-07-14
PE20170503A1 (es) 2017-05-11
EA202091342A3 (ru) 2020-12-30
BR112017001940A2 (pt) 2017-11-28
MA40721A (fr) 2017-06-13
JP2021000084A (ja) 2021-01-07
IL250007A0 (en) 2017-03-30
ES2986097T3 (es) 2024-11-08
CN113912737A (zh) 2022-01-11
IL275944A (en) 2020-08-31
SI3177307T1 (sl) 2024-09-30
MX388977B (es) 2025-03-20
EA201790063A1 (ru) 2017-06-30
EA035956B1 (ru) 2020-09-04
CL2017000284A1 (es) 2017-11-17
IL250007B (en) 2020-07-30
JP6723982B2 (ja) 2020-07-15
EP3177307B1 (en) 2024-07-17
HUE068478T2 (hu) 2025-01-28
MA40094B1 (fr) 2022-05-31
US20250163118A1 (en) 2025-05-22
CA2957273C (en) 2023-03-14
JP2023099045A (ja) 2023-07-11
US12084483B2 (en) 2024-09-10
AU2015301071B2 (en) 2020-03-05
FI3177307T3 (fi) 2024-10-04
KR20170030646A (ko) 2017-03-17
CA2957273A1 (en) 2016-02-11
SA517380842B1 (ar) 2021-12-26

Similar Documents

Publication Publication Date Title
AU2020203352B2 (en) Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
RU2711979C2 (ru) Белковый комплекс интерлейкина 15 и его применение
US8216576B2 (en) Method for inhibiting binding to B-cell receptor
US20050261477A1 (en) Pharmaceutical compositions and medical treatments comprising notch ligand proteins
JP2003533488A (ja) 免疫抑制を達成するための組成物および方法
KR20200070236A (ko) 면역치료제로서의 pd1-특이적 키메라 항원 수용체
KR20220131529A (ko) 변경된 icd stat 신호전달을 갖는 cd122
US20120164101A1 (en) Gm-csf and interleukin-21 conjugates and uses thereof in the modulation of immune response and treatment of cancer
HK40116369A (en) Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
HK1233501A1 (en) Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
HK1233501B (en) Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
EA045313B1 (ru) Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения
JP3689111B2 (ja) インターロイキン１５

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 MAR 2020

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 04 MAR 2020

FGA Letters patent sealed or granted (standard patent)